Brief: Sensei Biotherapeutics Announces Submission Of Investigational New Drug (Ind) Application For Sns-101, A Conditionally Active Vista-Blocking Antibody
21/03/2023 11:33
March 21 (Reuters) - Sensei Biotherapeutics Inc
SNSE.O :
* SENSEI BIOTHERAPEUTICS ANNOUNCES SUBMISSION OF
INVESTIGATIONAL
NEW DRUG (IND) APPLICATION FOR SNS-101, A CONDITIONALLY ACTIVE
VISTA-BLOCKING ANTIBODY
Source text for Eikon: ID:nGNXc0bvY4
Further company coverage: SNSE.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Faeth Therapeutics,
See all newsBrief: Sensei Biotherapeutics Announces Name Change To Faeth Therapeutics
Brief: Sensei Biotherapeutics Doses First Patient In Phase 1B/2 Trial Of Piktor In Hr+/Her2- Advanced Breast Cancer
Brief: Sensei Biotherapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)